Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6636890 | 0.85 | SLC6A4 (0.52) | HTR1ASLC6A4CNR1CNR2RORC | |
| SCHEMBL6635637 | 0.83 | SLC6A4 (0.55) | HTR1ASLC6A4CNR1CNR2KDM1A | |
| SCHEMBL6636242 | 0.81 | HTR1A (0.50) | HTR1ASLC6A4CNR1CNR2RORC | |
| SCHEMBL6639951 | 0.80 | HTR1A (0.52) | HTR1ASLC6A4CNR1CNR2PTGER4 | |
| SCHEMBL6635409 | 0.77 | SMO (0.51) | HTR1ASLC6A4CNR1CNR2DRD2 | |
| SCHEMBL6640261 | 0.71 | SLC6A4 (0.58) | HTR1ASLC6A4 | |
| SCHEMBL21661973 | 0.70 | NR3C1 (0.40) | HTR1ASLC6A4NR3C1PGRNR3C2 | |
| SCHEMBL20604601 | 0.70 | CNR1 (0.35) | SLC6A4CNR1CNR2LRRK2KDM1A | |
| SCHEMBL613836 | 0.67 | GRIA1 (0.36) | — | |
| SCHEMBL21525862 | 0.66 | HSD17B10 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946545-B1 | NOVEL CARBOXY SUBSTITUTED CYCLIC CARBOXAMIDE DERIVATIVES | AVENTIS PHARMA INC (US) | 2001-09-05 | — | — | EP | claimed |
| EP-1147083-B1 | ARYLPIPERAZINYL-CYCLOHEXYL INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | WYETH CORP (US) | 2004-06-16 | — | — | EP | disclosed |
| US-6465482-B2 | ANTIDEPRESSANTS; ANXIOLYTIC AGENTS; SEROTONIN-AFFECTED NERVOUS SYSTEM DISORDERS; ACTING AT THE 5-HT1A AUTORECEPTORS CONCOMMITANTLY WITH 5-HT TRANSPORTERS; ANTISEROTONIN AGENTS; SEROTONIN REUPTAKE INHIBITORS; HT3 RECEPTOR ANTAGONISTS | WYETH | 2002-10-15 | — | — | US | disclosed |
| US-20020045628-A1 | Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-04-18 | — | — | US | disclosed |
| US-6313126-B1 | FOR THRERAPY OF DISORDERS ASSOCIATED WITH DYSFUNCTION IN SEROTONERGIC NEUROTRANSMISSION, INCLUDING DEPRESSION AND ANXIETY | AMERICAN HOME PRODUCTS CORP | 2001-11-06 | — | — | US | disclosed |
| EP-1147083-A1 | ARYLPIPERAZINYL-CYCLOHEXYL INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000040554-A1 | ARYLPIPERAZINYL-CYCLOHEXYL INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045628-A1 | Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression | HTR2C, TPH1, TPH2 | HTR1A 9/4885SLC6A4 43/4885CNR1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.